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Summary
Objective:	 Patients	with	 chronic	 kidney	 disease	 (CKD)	 have	 dysregulated	 cortisol	
metabolism secondary to changes in 11β‐hydroxysteroid	dehydrogenase	(11β‐HSD)	
enzymes.	The	determinants	of	this	and	its	clinical	implications	are	poorly	defined.
Methods:	We	performed	a	cross‐sectional	study	to	characterize	shifts	in	cortisol	me‐
tabolism	in	relation	to	renal	function,	inflammation	and	glycaemic	control.	Systemic	
activation	of	cortisol	by	11β‐HSD was measured as the metabolite ratio (tetrahydro‐
cortisol	[THF]+5α‐tetrahydrocortisol [5αTHF])/tetrahydrocortisone	(THE)	in	urine.
Results:	The	cohort	included	342	participants	with	a	median	age	of	63	years,	median	
estimated	glomerular	filtration	rate	(eGFR)	of	28	mL/min/1.73	m2 and median urine 
albumin‐creatinine	ratio	of	35.5	mg/mmol.	(THF+5αTHF)/THE	correlated	negatively	
with	eGFR	(Spearman’s	ρ	=	−0.116,	P	=	0.032)	and	positively	with	C‐reactive	protein	
(ρ	=	0.208,	P	<	0.001).	In	multivariable	analysis,	C‐reactive	protein	remained	a	signifi‐
cant	 independent	 predictor	 of	 (THF+5αTHF)/THE,	 but	 eGFR	 did	 not.	 Elevated	
(THF+5αTHF)/THE	was	associated	with	HbA1c	(ρ	=	0.144,	P	=	0.008)	and	diabetes	
mellitus	(odds	ratio	for	high	vs	low	tertile	of	(THF+5αTHF)/THE	2.57,	95%	confidence	
interval	1.47‐4.47).	Associations	with	diabetes	mellitus	and	with	HbA1c	among	the	
diabetic	 subgroup	 were	 independent	 of	 eGFR,	 C‐reactive	 protein,	 age,	 sex	 and	
ethnicity.
Conclusions:	In	summary,	glucocorticoid	activation	by	11β‐HSD in our cohort com‐
prising	a	spectrum	of	renal	function	was	associated	with	inflammation	and	impaired	
glucose control.
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1  | INTRODUC TION
Glucocorticoids	(GCs)	are	steroid	hormones	that	play	a	critical	role	in	
regulating	 energy	metabolism,	 inflammation,	 cardiovascular	 function	
and	behavioural	processes.	In	excess,	GCs	drive	metabolic	disease,	in‐
sulin resistance and cardiovascular disease.1	Critical	 to	the	actions	of	
GCs	are	their	pre‐receptor	metabolism	by	the	11beta‐hydroxysteroid	
dehydrogenase (11β‐HSD)	type	1	and	type	2	enzymes.2 11β‐HSD1 is 
a	bidirectional	enzyme	that	primarily	converts	inactive	GC	(cortisone)	
to	its	active	counterpart	(cortisol)	and	is	widely	expressed	throughout	
the body.3	In	contrast,	11β‐HSD2	solely	inactivates	GCs	and	is	primar‐
ily	expressed	in	mineralocorticoid	sensitive	tissues	such	as	the	kidney.	
Together,	these	determine	local	tissue	exposure.
Several	studies	have	described	a	correlation	between	 loss	of	renal	
function	and	GC	activation	by	11β‐HSD	enzymes,	measured	as	 a	 rise	
in	the	ratio	of	cortisol/cortisone	or	a	rise	in	the	ratio	of	their	respective	
metabolites	 (tetrahydrocortisol	 [THF]+5α‐tetrahydrocortisol [5αTHF])/
tetrahydrocortisone	 (THE).4,5	 Due	 to	 limitations	 of	 measuring	 steroid	
metabolism	in	this	way,	the	relative	contribution	of	each	11β‐HSD en‐
zyme	to	the	reported	shift	in	cortisol	metabolism	is	not	known.	Loss	of	
renal	expression	of	11β‐HSD2	and	diminished	cortisol	inactivation	likely	
plays	a	role.6	However,	 in	vitro	and	animal	models	of	uraemia	propose	
concurrent 11β‐HSD1	upregulation	and	associated	cortisol	generation.7,8
Chronic	 kidney	 disease	 (CKD)	 entails	 a	 pro‐inflammatory	 state.9 
Pro‐inflammatory	cytokines	are	potent	inducers	of	11β‐HSD1	activity,	
promoting	local	GC	activation	both	in	vitro	and	in	vivo.10,11	Upregulation	
of	11β‐HSD1	expression	occurs	in	several	human	inflammatory	condi‐
tions	with	a	strong	correlation	between	systemic	measures	of	inflam‐
mation and increases in cortisol activation.12,14	Existing	studies	in	CKD	
have	not	evaluated	 inflammation	as	a	driver	of	11β‐HSD1 activity or 
GC	activation.
The	 inflammatory	 activation	 in	 CKD	 contributes	 to	 insulin	 resis‐
tance.15,16	 Insulin	 resistance	manifests	 from	the	early	 stages	of	 renal	
impairment,	and	diabetes	mellitus	co‐exists	in	one	third	of	people	with	
CKD.16,18,19	Disturbances	in	glucose	metabolism	in	the	context	of	CKD	
are	independently	associated	with	cardiovascular	disease,	accelerated	
loss	 of	 renal	 function	 and	 death.16,18,19	 Elevated	 11β‐HSD1 activity 
has	 been	 implicated	 in	metabolic	 disease	 and	 insulin	 resistance.23,24 
Suppression	of	11β‐HSD1	activity	protects	against	insulin	resistance	in	
murine	models,	including	models	of	uraemia,	and	has	improved	HbA1c	
in	Phase	II	clinical	trials	for	type	2	diabetes.7,26,27 Whether elevated 11β‐
HSD1	activity	is	involved	in	insulin	resistance	in	the	setting	of	human	
CKD	has	not	yet	been	explored.
Given	the	central	role	of	inflammation	in	regulating	cortisol	activa‐
tion via 11β‐HSD1,	we	investigated	its	association	with	shifts	in	the	cor‐
tisol‐cortisone	equilibrium	in	human	CKD.	Furthermore,	we	examined	
whether	augmented	GC	activation	in	CKD	relates	to	impaired	glucose	
handling.	To	test	this,	we	performed	a	cross‐sectional	study	with	342	
participants	 representing	 a	 broad	 spectrum	 of	 renal	 function.	 Using	
urine	(THF+5αTHF)/THE	as	a	validated	indicator	of	systemic	11β‐HSD‐
mediated	GC	activation,	we	examined	its	correlation	with	renal	func‐
tion,	inflammation	and	glycaemic	control	in	CKD.5,30,31
2  | MATERIAL S AND METHODS
2.1 | Participants
This	 study	 included	 331	 participants	 with	 CKD	 and	 11	 healthy	
individuals	 without	 kidney	 disease.	 The	 Renal	 Impairment	 in	
Secondary	 Care	 (RIISC)	 observational	 study	 cohort	 provided	
the	 sampling	 frame	 for	 cases	 with	 CKD.	 Patient	 enrolment	 for	
RIISC	took	place	at	two	teaching	hospitals	in	Birmingham,	United	
Kingdom,	 between	 2010	 and	 2015.	 The	 eligibility	 criteria	 have	
been described in detail elsewhere.33	 In	 brief,	 patients	 in	 RIISC	
had	 CKD	 stage	 3	 with	 declining	 estimated	 glomerular	 filtration	
rate	 (eGFR)	 of	 ≥5	mL/min/1.73	m2/y	 or	 ≥10	mL/min/1.73	m2/5 y 
or	proteinuria	with	urinary	albumin‐creatinine	ratio	(ACR)	≥70	mg/
mmol,	 or	 CKD	 stage	 4/5.	 Patients	 receiving	 renal	 replacement	
therapy	 or	 immunosuppressive	 treatment	 were	 excluded	 from	
the	RIISC	cohort.	From	a	 total	of	932	cases	 in	 the	RIISC	cohort,	
299	cases	with	incomplete	biochemical	data	sets	and	25	cases	re‐
ceiving	 systemic	GC	 treatment	were	excluded	prior	 to	 sampling.	
In	 total,	 333	 cases	 of	 608	 eligible	 cases	 were	 sampled	 for	 this	
study	 to	 obtain	 the	 desired	 sample	 size	 (see	 Statistical	 Analysis	
for	 power	 calculation).	 A	 stratified	 random	 sampling	 procedure	
was	 employed	 to	 balance	 the	 proportions	 of	 cases	 with	 eGFR	
≤15,	15‐30,	30‐45	and	≥45	mL/min/m2	and	to	avoid	oversampling	
cases	from	a	narrow	band	of	low	eGFR	which	were	preferentially	
enrolled	in	the	RIISC	cohort.	Two	cases	had	to	be	excluded	in	the	
experimental	process	due	to	technical	failures.
Healthy	individuals	were	recruited	from	the	control	arm	of	an	on‐
going	study	at	the	University	of	Birmingham	characterizing	immune	
dysfunction	 in	 older	 patients	with	CKD.	These	 individuals	 did	 not	
have	any	known	renal	or	 inflammatory	disease	and	were	not	using	
systemic	GC	treatment	at	the	time	of	study	enrolment.	The	rationale	
for	inclusion	of	a	small	group	of	healthy	individuals	in	analyses	was	
to	gain	better	insight	into	how	changes	in	renal	function	affect	glu‐
cocorticoid activation by 11β‐HSD,	as	cases	with	normal	renal	func‐
tion	and	no	active	inflammation	are	underrepresented	in	the	RIISC	
cohort.
Use	 of	 data	 and	 samples	 for	 this	 research	 falls	 under	 ethical	
approvals	granted	by	the	South	Birmingham	Local	Research	Ethics	
committee	(participants	with	CKD;	reference	10/H1207/6)	and	the	
Edgbaston	Research	Ethics	Committee	 (participants	without	CKD;	
reference	 15/WM/0057).	 All	 participants	 provided	 written	 in‐
formed	consent,	and	the	study	was	conducted	 in	accordance	with	
the	Declaration	of	Helsinki.
2.2 | Baseline assessment
Study	participants’	 demographic	 information,	 past	medical	 history	
and	 concomitant	 medications	 were	 taken	 from	 medical	 records.	
Diabetes	mellitus	was	defined	by	history	of	 diet‐controlled	diabe‐
tes,	treatment	with	anti‐diabetic	medications	or	HbA1c	greater	than	
48 mmol/mol.
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Laboratory	 measurements	 included	 routine	 blood	 haematologi‐
cal	profiles	(Haematology	Analyser,	Beckman	Coulter,	Brea,	CA,	USA)	
and	 blood	 biochemical	 profiles	 and	 urinary	ACR	 (Roche	Hitachi	 702	
Analyser,	Basel,	Switzerland).	eGFR	was	derived	from	the	serum	cre‐
atinine‐based	 CKD‐EPI	 equation.	 CRP	 was	 measured	 using	 the	 Full	
Range	C‐Reactive	Protein	SpaPlus	assay	(The	Binding	Site,	Birmingham,	
UK)	for	participants	with	CKD	and	the	CRP	High	Sensitive	ELISA	(IBL,	
Hamburg,	Germany)	for	volunteers	without	renal	disease.
2.3 | Urinary steroid measurements
The	balance	of	systemic	(ie,	total	body)	cortisol‐cortisone	intercon‐
version by 11β‐HSD	enzymes	was	taken	as	the	ratio	calculated	from	
the	 urinary	 excretion	 of	 (THF+5αTHF)/THE.	 This	 methodology	 is	
well	 established	 as	 reflective	of	11β‐HSD1	activity	 and	has	previ‐
ously	been	validated	in	the	literature,30,31	including	the	use	of	early	
morning	spot	urine	samples.5,34
Spot	 urine	 samples	were	 collected	 at	morning	 clinic	 visits	 and	
stored	at	−80°C	until	analysis.	Steroids	were	extracted	from	400	µL	
of	urine	based	on	a	previously	 reported	protocol.35 The urine was 
spiked	with	0.4	µg	of	internal	standard	(THE‐d5,	THF‐d5;	purchased	
from	Isosciences,	Ambler,	PA,	USA),	and	the	steroids	hydrolysed	to	
remove	 their	 conjugate	groups	 (sulphate	 and/or	 glucuronide).	 This	
was	achieved	by	heating	the	urine	for	3	hours	at	60°C	in	a	hydroly‐
sis	buffer	(400	μL	of	0.2	mol/L	acetate	buffer	pH	4.8‐5:	with	10	mg	
sulphatase	 [adjusted	 based	 on	 batch	 activity]	 and	 10	mg	 ascor‐
bate/3	mL	of	solvent).	The	now	“free”	deconjugated	steroids	were	
subsequently	extracted	by	solid	phase	extraction	using	96‐well	C18 
cartridges	in	a	positive	pressure	manifold,	eluting	with	1	mL	of	meth‐
anol.	The	samples	were	dried	at	50°C	under	nitrogen	and	reconsti‐
tuted	 in	 125	µL	 of	 50/50	methanol/water	 for	 analysis	with	 liquid	
chromatography‐tandem	mass	spectrometry	(uPLC‐MS/MS).
A	Waters	Xevo	mass	spectrometer	coupled	to	an	Acquity	uPLC	
with	 an	electrospray	 ionization	 source	 in	positive	 ionization	mode	
was	utilized	in	these	experiments.	THE,	THF	and	5αTHF	were	sep‐
arated	on	a	BEH	C18	1.7	µm	5	cm	column	at	60°C	with	the	mobile	
phases	methanol	 and	water	 both	with	 0.1%	 formic	 acid.	Gradient	
profile	was	starting	at	30%	methanol,	hold	for	one	minute	then	a	lin‐
ear	gradient	to	60%	methanol	at	5	minutes,	followed	by	washing	and	
re‐equilibration	steps.	Steroids	were	identified	by	comparison	to	au‐
thentic	reference	standards,	(THE,	THF	and	5αTHF	purchased	from	
Steraloids,	Newport,	RO,	USA),	with	a	matching	retention	time	and	
identical	mass	 transitions	 (MRMs)	 required	 for	 positive	 identifica‐
tion	(Supporting	Information	Table	S1	and	Figure	S1).	Steroids	were	
quantified	relative	to	a	calibration	series	ranging	from	10‐5000	ng/
mL	prepared	 in	 synthetic	urine,	 including	a	blank.	Steroid	concen‐
trations were calculated relative to an assigned internal standard. 
Validation	of	this	method	is	described	in	the	supplementary	section	
(Supporting	Information	Table	S2).	Measurements	of	urinary	cortisol	
and	cortisone	for	supplementary	analysis	followed	similar	principles,	
and	full	details	for	this	methodology	are	provided	in	the	supplemen‐
tary	materials	 (Supporting	 Information	Appendix	 S1,	 Table	 S1	 and	
Figure	S2).
2.4 | Statistical analysis
Data	for	continuous	variables	were	not	normally	distributed.	Mann‐
Whitney U	 test,	 Kruskal‐Wallis	 test	 followed	 by	 Dunn’s	 multiple	
comparisons	test	and	Spearman’s	correlation	test	were	used	as	ap‐
propriate.	For	multiple	linear	regression	analysis,	outcome	variables	
were	log‐transformed	to	comply	with	the	requisite	statistical	assump‐
tions.	For	binary	logistic	regression	analysis,	urinary	(THF+5αTHF)/
THE	ratio,	eGFR	and	CRP	did	not	comply	with	the	linearity	assump‐
tion	of	 independent	 variables	 and	 log	odds.	 These	were	 therefore	
included	as	log‐transformed	variables	(CRP)	or	as	stratified	variables	
(tertiles	for	urine	(THF+5αTHF)/THE	with	limits	≤0.983,	0.983‐1.586	
and	>1.586;	 clinical	CKD	 stages	 for	 eGFR	with	≤15,	 15‐30,	 30‐45	
and	 >45	mL/min/1.73	m2).	 Cases	with	missing	 values	were	 not	 in‐
cluded	in	multivariable	analyses,	but	this	applied	to	≤3.2%	of	cases	
for	any	reported	model.	Results	were	deemed	statistically	significant	
at P	<	0.05.	Sample	size	estimation	considered	that	a	covariate	added	
to	 a	 baseline	 linear	 regression	model	 for	 urine	 (THF+5αTHF)/THE	
with assumed R2	=	0.10	 producing	 an	 increment	 to	R2	≥	0.025	will	
be	identified	as	statistically	significant	at	P	≤	0.05	with	power	0.80	
for	n	=	282.	The	final	sample	size	 included	a	redundancy	margin	of	
15‐20	per	cent.	Analyses	were	performed	using	IBM	SPSS	Statistics	
for	Windows	Version	23	(IBM	Corp;	Armonk,	NY,	USA).
3  | RESULTS
The	clinical	and	laboratory	characteristics	of	the	study	participants	
are	 summarized	 in	 Table	 1	 (for	 break‐down	 by	 aetiology	 of	 renal	 
disease	see	Supporting	Information	Table	S3).
3.1 | Renal diagnosis and function
Previous	 studies	 have	 reported	 increasing	 GC	 activation	 by	 11β‐
HSD	enzymes	with	declining	 renal	 function,4,6 which we tested in 
our	 larger	 cohort.	 Urine	 (THF+5αTHF)/THE	was	 elevated	 in	 renal	
disease	regardless	of	aetiology	compared	to	healthy	volunteers,	ex‐
cept	for	polycystic	renal	disease	(Figure	1A).	Among	cases	with	renal	
disease,	 urine	 (THF+5αTHF)/THE	 was	 lowest	 in	 polycystic	 renal	
disease	and	highest	in	diabetic	nephropathy.	As	in	previous	reports,	
we	 found	a	negative	but	weak	 correlation	of	urine	 (THF+5αTHF)/
THE	 with	 eGFR	 (ρ =	−0.116,	 P	=	0.032;	 Figure	 1B).	 There	 was	 no	
association	 with	 urinary	 albumin‐creatinine	 ratio	 (ACR;	 ρ	=	0.014,	
P	=	0.796;	Figure	1C).	These	 results	 consolidate	previous	observa‐
tions	that	people	with	renal	 impairment	have	higher	GC	activation	
by 11β‐HSD.
3.2 | Inflammation
Chronic	kidney	disease	is	known	to	entail	a	pro‐inflammatory	state.9 This 
was	apparent	in	our	cohort	in	the	negative	correlation	for	eGFR	with	C‐
reactive	protein	 (CRP;	ρ	=	−0.281,	P	<	0.001;	Figure	2A).	 Importantly,	
we	identified	a	significant	positive	correlation	between	CRP	and	urine	
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(THF+5αTHF)/THE	(ρ	=	0.208,	P	<	0.001;	Figure	2B).	This	 is	reflected	
in	the	earlier	observation	of	relatively	low	urine	(THF+5αTHF)/THE	in	
patients	with	polycystic	kidney	disease,	as	this	subgroup	also	exhibited	
low	CRP	 (Supporting	 Information	Table	S3).	We	constructed	a	multi‐
variable	linear	regression	model	to	explore	independent	determinants	
of	urine	(THF+5αTHF)/THE.	Covariates	included	demographic	factors,	
markers	of	renal	function	(eGFR,	urine	ACR),	 inflammation	(CRP)	and	
glycaemic	control	(HbA1c)	(Table	2).	 Inflammation	remained	indepen‐
dently	associated	with	urine	(THF+5αTHF)/THE.	However,	there	was	
no	independent	relationship	between	eGFR	and	urine	(THF+5αTHF)/
THE	in	the	multiple	linear	regression	model.	This	suggests	that	GC	ac‐
tivation by 11β‐HSD	is	more	closely	associated	with	inflammation	than	
with	renal	function	in	this	CKD	cohort.
3.3 | Diabetes mellitus
High 11β‐HSD1	activity	 leads	to	metabolic	dysfunction	and	impaired	
insulin	 signalling,	 but	 this	 has	 not	 yet	 been	 tested	 in	 human	 CKD.	
Having	identified	that	glucocorticoid	activation	by	11β‐HSD is elevated 
in	CKD,	we	examined	the	association	of	urine	(THF+5αTHF)/THE	with	
prevalent	 diabetes.	 Participants	 with	 known	 diabetes	 mellitus	 had	
higher	 urine	 (THF+5αTHF)/THE	 (median	 [interquartile	 range	 (IQR)]:	
1.51	 [0.97‐1.87]	vs	1.14	 [0.81‐1.61],	P	=	0.007;	Figure	3A).	 eGFR	was	
not	significantly	different	between	those	with	or	without	diabetes	(me‐
dian	[IQR]:	26.0	[16.5‐37.3]	vs	29.1	[17.7‐47.5],	P	=	0.142),	but	CRP	was	
higher	 in	 those	with	diabetes	 (median	 [IQR]:	3.40	 [2.12‐9.51]	vs	2.25	
[1.08‐4.84],	P	<	0.001).	We	controlled	for	the	potential	confounding	in‐
fluence	of	CRP,	eGFR	and	demographic	factors	by	using	multivariable	
logistic	regression	analysis	(Table	3;	urine	(THF+5αTHF)/THE	and	eGFR	
were	categorized	for	this	analysis	to	comply	with	the	requisite	statisti‐
cal	assumptions	as	detailed	in	the	methods	section).	The	association	of	
high	urine	(THF+5αTHF)/THE	with	diabetes	was	independent	of	these	
covariates.	The	association	also	persisted	after	 the	 inclusion	of	body	
mass	index	and	family	history	of	diabetes	as	additional	covariates.	This	
supports	a	link	between	glucocorticoid	activation	by	11β‐HSD and dia‐
betes	mellitus	in	our	CKD	cohort.
3.4 | HbA1c and poor glycaemic control
To	 further	 corroborate	 the	 link	 between	 elevated	 GC	 activation	 by	
11β‐HSD	with	impaired	glucose	metabolism	in	CKD,	we	assessed	the	
relationship	of	GC	activation	by	11β‐HSD	with	HbA1c.	HbA1c	was	pos‐
itively	correlated	with	urine	(THF+5αTHF)/THE	(ρ	=	0.144,	P = 0.008; 
Figure	 3B).	 HbA1c	 also	 exhibited	 a	 negative	 association	 with	 eGFR	
(ρ	=	−0.127,	P	=	0.020)	and	a	positive	association	with	CRP	(ρ	=	0.337,	
P	<	0.001)	 in	our	cohort.	We	controlled	 for	 these	covariates	and	de‐
mographic	factors	 in	a	multiple	 linear	regression	analysis.	Age,	South	
Asian	ethnicity	and	CRP	remained	associated	with	HbA1c	(P	<	0.001,	
P < 0.001 and P	=	0.001,	 respectively;	 Supporting	 Information	 Table	
S5),	but	urine	(THF+5αTHF)/THE	did	not	show	an	independent	asso‐
ciation	in	the	full	cohort	(P	=	0.659;	Supporting	Information	Table	S5).	
We	considered	that	 the	association	of	urine	 (THF+5αTHF)/THE	with	
HbA1c	could	be	weakened	by	inclusion	of	the	non‐diabetic	population,	
as homoeostatic mechanisms that counter‐regulate increased insulin 
resistance	are	effective	 in	 this	population	and	variability	 in	HbA1c	 is	
low.	Applying	the	same	multiple	linear	regression	model	as	before,	we	
identified	an	independent	association	of	urine	(THF+5αTHF)/THE	with	
HbA1c	in	the	subgroup	of	patients	with	diabetes	(P	=	0.034;	Supporting	
Information	Table	S5).	Taken	together,	these	results	indicate	an	associa‐
tion	of	GC	activation	by	11β‐HSD and disturbances in glucose metabo‐
lism	in	the	context	of	renal	impairment.
3.5 | Urinary cortisol‐cortisone ratio
A	supplementary	analysis	of	urinary	cortisol‐cortisone	ratio	identified	
no	significant	association	with	eGFR,	CRP,	prevalent	diabetes	mellitus	
or	HbA1c	(Supporting	Information	Figure	S3).
4  | DISCUSSION
Previous	 studies	 in	 patients	 with	 CKD	 have	 suggested	 that	 in‐
creasing	 (THF+5αTHF)/THE	 ratios,	 favouring	 systemic	 cortisol	
TA B L E  1  Cohort	characteristics
Variable Value
n 342
Age	(y) 63	(50‐75)
Female 134	(39%)
Ethnicity
White 242	(71%)
South Asian 62	(18%)
Black 35	(10%)
Other 3	(1%)
Aetiology	of	renal	disease
Ischaemic/hypertensive 70	(20%)
Glomerulonephritis 70	(20%)
Polycystic 32	(9%)
Diabetic 31	(9%)
Obstructive/reflux 24	(7%)
Interstitial	disease 19	(6%)
Not	known	and	other 85	(25%)
No	renal	disease 11	(3%)
eGFR	(mL/min/1.73	m2) 28	(18‐43)
Urine	ACR	(mg/mmol) 35.5	(5.4‐120.6)
Diabetes 122	(36%)
HbA1c	(mmol/mol) 42	(38‐50)
C‐reactive	protein	(mcg/mL) 2.7	(1.2‐6.3)
Urine	(THF+5αTHF)/THE 1.23	(0.86‐1.80)
Continuous	 variables	 are	 reported	 as	median	 (interquartile	 range)	 and	
categorical	variables	as	frequency	(percentage).
ACR,	 albumin‐creatinine	 ratio;	 eGFR,	 estimated	 glomerular	 filtration	
rate;	 (THF+5αTHF)/THE,	 tetrahydrocortisol+5α‐tetrahydrocortisol/
tetrahydrocortisone.
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activation,	 are	 determined	 by	 declining	 renal	 function	 and	 at‐
tenuated renal steroid clearance by 11β‐HSD2.4,5	Our	study	con‐
firmed	 that	 GC	 activation	 by	 11β‐HSD	 is	 elevated	 in	 CKD,	 but	
identified	 inflammation	as	a	crucial	modifying	 factor	 in	 this	 set‐
ting.	Furthermore,	we	identified	an	association	between	increas‐
ing	(THF+5αTHF)/THE	ratio	with	impaired	glucose	control	in	this	
CKD	cohort.
Inflammation,	 measured	 as	 CRP,	 was	 the	 dominant	 explan‐
atory	 variable	 for	 urine	 (THF+5αTHF)/THE	 in	 our	 data	 and	
significantly	diminished	the	effect	of	eGFR	as	a	covariate.	The	as‐
sociation	between	urine	(THF+5αTHF)/THE	and	eGFR	was	not	as	
strong	as	values	previously	reported	in	the	literature.4,6	Cohorts	
in	 previous	 studies	 were	 smaller,	 used	 sampling	 methodologies	
with	greater	potential	for	bias	and	included	a	majority	of	partici‐
pants	with	eGFR	>60	mL/min/1.73	m2.	In	contrast,	the	cohort	in	
this	study	is	more	representative	of	a	high‐risk	CKD	population.
Previous	 studies	 did	 not	 control	 for	 inflammation,	 which	 is	
concomitant	 with	 renal	 impairment.	 Inflammation	 is	 a	 potent	
inducer	 of	 11β‐HSD1	 expression	 and	 activity,	 with	 significant	
increases in cortisol activation by 11β‐HSD1 seen in several 
inflammatory	 diseases.11,12,14,34,36,37 Whilst this study cannot 
accurately discriminate between the 11β‐HSD	 types	 1	 and	 2	
contributions	to	systemic	GC	metabolism,	 it	 is	unlikely	that	our	
findings	 are	 solely	 attributable	 to	 loss	 of	 renal	 cortisol	 inacti‐
vation by 11β‐HSD2.	 The	 inflammatory	 cytokines	 TNFα and 
IL‐1β,	which	accumulate	in	uraemia,	are	potent	inducers	of	11β‐
HSD1.9,11	Furthermore,	studies	in	human	hepatocytes	and	animal	
models	of	uraemia	report	marked	 increases	 in	11β‐HSD1 activ‐
ity.7,8	Our	results	are	 therefore	consistent	with	a	growing	body	
of	evidence	that	increased	inflammatory	induction	of	11β‐HSD1 
contributes	considerably	to	abnormal	GC	metabolism	in	patients	
with	CKD.
In	 this	 study,	 we	 demonstrate	 that	 diabetes,	 and	 HbA1c	
among	patients	with	diabetes,	 is	 associated	with	elevated	urine	
(THF+5αTHF)/THE	 in	CKD.	 The	 association	 of	 impaired	 glycae‐
mic	 control	 with	 shifts	 in	 cortisol	 metabolism	 remained	 after	
adjustment	 for	 age,	 sex,	 ethnicity,	 renal	 function	and	 inflamma‐
tion.	These	 results	 align	with	 a	 large	body	of	 evidence	 that	 has	
established	insulin	resistance	as	a	consequence	of	increased	11β‐
HSD1 activity in animal models and human disease.7,23,24,26‐29 The 
absence	 of	 a	 correlation	 between	 urine	 (THF+5αTHF)/THE	 and	
HbA1c	in	the	non‐diabetic	subgroup	can	be	explained	by	a	lack	of	
change	in	HbA1c	regardless	of	insulin	resistance,	as	accompany‐
ing	insulin	secretion	increases	sufficiently	to	maintain	glycaemic	
F I G U R E  1  Association	of	urine	(THF+5αTHF)/THE	with	renal	diagnosis	and	function.	A,	Urine	(THF+5αTHF)/THE	is	higher	in	renal	
disease	regardless	of	aetiology,	except	for	polycystic	renal	disease.	Urine	(THF+5αTHF)/THE	is	significantly	different	for	polycystic	vs	
diabetic	renal	disease,	but	not	for	other	comparisons	by	aetiology	of	renal	disease.	(THF+5αTHF)/THE	is	displayed	on	a	discontinuous	scale	
to	show	outliers	that	were	included	in	the	analysis.	Beams	and	whiskers	indicate	group	medians	and	interquartile	ranges,	respectively;	
numbers	in	parentheses	indicate	cases	per	group.	Group	comparisons	used	Dunn's	multiple	comparisons	test:	*P	<	0.05,	**P	<	0.01,	
***P	<	0.001	vs	no	renal	disease.	B,	Urine	(THF+5αTHF)/THE	correlates	negatively	with	renal	function,	but	(C)	does	not	correlate	with	
albuminuria.	Urinary	ACR	is	displayed	on	a	log	scale.	Spearman's	test	was	used	to	assess	correlations.	ACR,	albumin‐creatinine	ratio;	eGFR,	
estimated	glomerular	filtration	rate;	(THF+5αTHF)/THE,	tetrahydrocortisol+5α‐tetrahydrocortisol/tetrahydrocortisone
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control.18	 Our	 data	 therefore	 remain	 consistent	 with	 a	 role	 for	
11β‐HSD1	in	insulin	resistance	in	human	CKD.
Inflammation	is	a	known	driver	for	insulin	resistance	in	CKD.	
This	is	evident	by	CRP	showing	a	negative	correlation	with	eGFR	
and	an	independent	positive	correlation	with	HbA1c	in	this	study.	
Pro‐inflammatory	cytokines	TNFα	and	IL‐1	accumulate	in	CKD	in	
serum,	as	well	as	in	insulin	target	tissues,	where	they	act	on	IRS‐1	
and	 PKB/Akt	 to	 impede	 post‐receptor	 insulin	 signal	 transduc‐
tion.15,16	 In	 the	 same	 tissues,	 in	 vitro	experiments	have	demon‐
strated	the	capability	of	TNFα	and	IL‐1β	to	upregulate	11β‐HSD1,	
which in turn also causes insulin resistance through action on 
IRS‐1	and	PKB/Akt.11,25	Existing	biochemical	data	therefore	illus‐
trate	a	coherent	pathway	through	which	 inflammation‐mediated	
upregulation	of	11β‐HSD1	leads	to	insulin	resistance.	Importantly,	
this	opens	11β‐HSD1	inhibition	as	a	therapeutic	target	in	CKD	to	
treat	insulin	resistance—and	possibly	other	disturbances	like	dys‐
lipidaemia—for	which	 a	 proof	 of	 concept	 experiment	 in	 rodents	
has	already	been	successful.7
Urinary	 cortisol‐cortisone	 ratio	 exhibited	 a	 moderate	 cor‐
relation with renal 11β‐HSD2	expression	 in	a	previous	study	by	
Quinkler	et	al6.	An	association	between	renal	function	and	corti‐
sol‐cortisone	ratios	in	24	hour	urine	samples	has	been	described	
in some but not all studies.4,6,40	In	this	study,	we	did	not	identify	
any	 significant	 correlations	 between	 urinary	 cortisol‐cortisone	
ratios	with	eGFR,	nor	with	CRP	or	Hb1Ac.	These	divergent	results	
may	reflect	significant	heterogeneity	between	study	populations,	
F I G U R E  2  Correlation	of	inflammation	with	renal	function	and	urine	(THF+5αTHF)/THE.	A,	Inflammation,	measured	by	C‐reactive	
protein,	is	negatively	correlated	with	eGFR	and	(B)	positively	correlated	with	urine	(THF+5αTHF)/THE	ratio.	C‐reactive	protein	is	
displayed	on	a	log	scale.	Spearman's	test	was	used	to	assess	correlations.	eGFR,	estimated	glomerular	filtration	rate;	(THF+5αTHF)/THE,	
tetrahydrocortisol+5α‐tetrahydrocortisol/tetrahydrocortisone
TA B L E  2   Independent	determinants	of	11β‐HSD‐mediated	glucocorticoid	activation	(n	=	337)
Variable B SE β t P
Age	(y) 1.13 × 10−3 1.94 × 10−3 0.035 0.58 0.560
Sex
Male Reference
Female −0.143 0.058 −0.130 −2.47 0.014
Ethnicity
White Reference
South Asian 0.104 0.078 0.074 1.33 0.185
Black 0.208 0.094 0.119 2.20 0.028
Other −0.565 0.300 −0.099 −1.89 0.060
eGFR	(mL/min/1.73	m2) −1.76	×	10−3 1.34 × 10−3 −0.075 −1.31 0.191
Urine	ACR	(mg/mmol) 3.43 × 10−5 2.40 × 10−4 0.008 0.14 0.886
C‐reactive	protein	(mcg/ml) 6.72 × 10−3 2.14 × 10−3 0.172 3.14 0.002
HbA1c	(mmol/mol) 3.08 × 10−3 2.39 × 10−3 0.074 1.29 0.198
Multivariable	linear	regression	analysis	with	dependent	variable	loge‐transformed	urine	(THF+5αTHF)/THE.	Adjusted	R
2 =	0.083.	Exclusion	of	the	11	
healthy	 volunteer	 cases	 from	 the	 analysis	 or	 substitution	 of	 HbA1c	 with	 diagnosis	 of	 diabetes	 does	 not	 significantly	 impact	 on	 the	 displayed	
parameters.
ACR,	albumin‐creatinine	ratio;	eGFR,	estimated	glomerular	filtration	rate;	(THF+5αTHF)/THE,	tetrahydrocortisol+5α‐tetrahydrocortisol/tetrahydro‐
cortisone; 11β‐HSD,	11β‐hydroxysteroid	dehydrogenase.
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or	 that	 spot	 urines	 lack	 sufficient	 sensitivity	 to	 detect	 these	
changes.
Several strengths and limitations are worth noting about this study. 
The	observational	design	produced	results	that	demonstrate	associa‐
tions	between	 shifts	 in	 glucocorticoid	metabolism,	 inflammation	 and	
impaired	glucose	metabolism,	but	cannot	confirm	causal	relationships.	
By	choosing	this	design,	it	was	nevertheless	possible	to	test	predictions	
from	pre‐clinical	models,	which	link	inflammation	with	raised	11β‐HSD1 
activity	and	insulin	resistance,	in	the	clinical	setting	and	thereby	provid‐
ing	new	evidence	for	the	significance	of	this	pathway	in	human	disease.	
The	study	cohort	was	large	and	diverse,	which	permitted	control	for	po‐
tential	confounders,	strengthens	the	validity	of	the	results	and	enhances	
their	relevance	for	people	with	CKD.	Measuring	urine	metabolite	ratios	
by	liquid	chromatography‐mass	spectrometry	as	indicator	of	11β‐HSD 
activity,	whilst	offering	high	convenience	for	a	large	study	population,	
limits conclusions about 11β‐HSD	type‐	or	tissue‐specific	alterations.	
Alterations in 11β‐HSD	activity	lead	to	much	more	pronounced	shifts	of	
cortisol‐cortisone	equilibrium	in	local	tissues	than	in	circulation,7 mean‐
ing	that	correlations	of	 inflammation	and	insulin	resistance	with	 local	
11β‐HSD activities could be much stronger than what can be observed 
by	measuring	systemic	metabolite	ratios.	Future	research	with	method‐
ologies	that	characterize	11β‐HSD	type‐	and	tissue‐specific	alterations	
in	humans	with	CKD	will	be	valuable	for	building	on	our	results.	Finally,	
it	would	be	relevant	to	investigate	whether	elevated	GC	activation	by	
11β‐HSD	associates	not	only	with	impaired	glycaemic	control,	but	also	
with	cardiovascular	morbidity,	progression	of	renal	disease	or	mortality.
Examination	of	basal	serum	cortisol	levels	or	total	urinary	GC	excre‐
tion	would	add	additional	validation	of	our	findings,	helping	delineate	
potential	 contributions	 of	 the	 hypothalamic‐pituitary‐adrenal	 (HPA)	
axis	to	our	results.	Without	timed	serum	samples	or	urine	samples	from	
a	fixed	collection	period	for	our	cohort,	we	were	unable	to	control	di‐
rectly	 for	 systemic	 cortisol	 levels	or	HPA	axis	 activity.	Nevertheless,	
previous	studies	validated	the	specificity	of	urine	 (THF+5αTHF)/THE	
for	alterations	 in	11β‐HSD	activity	over	changes	 in	HPA	axis	activity	
and	 found	 no	 correlation	 between	 total	 GC	metabolite	 excretion	 as	
a	measure	of	HPA	axis	activity	and	renal	 function.4,6,31,32	Neither	do	
fluctuations	 in	 systemic	 cortisol	 interfere	 with	 urine	 (THF+5αTHF)/
THE.41	Importantly,	basal	cortisol	levels,	as	well	as	the	fraction	of	pro‐
tein	bound	cortisol	 (90%‐95%),	do	not	change	significantly	with	renal	
impairment.42,43	 We	 therefore	 argue	 that	 associations	 with	 urine	
(THF+5αTHF)/THE	 in	our	study	reflect	systemic	11β‐HSD regulation 
rather	than	systemic	cortisol	levels	or	HPA	axis	activity.
In	conclusion,	this	study	assessed	systemic	cortisol	metabolism	by	
11β‐HSD	enzymes	in	a	large	cohort	of	patients	with	pre‐dialysis	chronic	
F I G U R E  3  Association	of	urine	(THF+5αTHF)/THE	with	diabetes	mellitus	and	glycaemic	control.	A,	Urinary	(THF+5αTHF)/THE	ratio	
was	elevated	in	prevalent	diabetes	and	(B)	correlated	positively	with	HbA1c,	a	measure	of	poor	glycaemic	control.	(THF+5αTHF)/THE	is	
displayed	on	a	discontinuous	scale	to	show	outliers	that	were	included	in	the	analysis.	Beams	and	whiskers	indicate	group	medians	and	
interquartile	ranges,	respectively;	numbers	in	parentheses	indicate	cases	per	group.	The	Mann‐Whitney	U	test	was	used	to	compare	groups;	
Spearman's	test	was	used	to	assess	correlations.	(THF+5αTHF)/THE,	tetrahydrocortisol+5α‐tetrahydrocortisol/tetrahydrocortisone
TA B L E  3  Adjusted	odds	ratio	for	the	association	of	glucocorticoid	activation	by	11β‐HSD	with	prevalent	diabetes	mellitus
n
Urine (THF+5αTHF)/THE
Low tertile
Middle tertile High tertile
OR 95% CI P OR 95% CI P
Unadjusted 342 Ref. 1.36 0.77‐2.42 0.289 2.57 1.47‐4.47 0.001
Model	A 342 Ref. 1.30 0.70‐2.40 0.403 1.97 1.07‐3.62 0.029
Model	B 331 Ref. 1.22 0.63‐2.35 0.556 2.09 1.09‐4.02 0.027
Binary	logistic	regression	analysis	for	the	association	of	urine	(THF+5αTHF)/THE	(stratified	by	tertiles)	with	prevalent	diabetes.	Model	A:	adjustment	
for	age,	sex,	ethnicity,	estimated	glomerular	filtration	rate	 (stratified	for	≤15,	15‐30,	30‐45	and	>45	mL/min/1.73	m2)	and	C‐reactive	protein	 (loge‐
transformed).	Model	B:	as	in	Model	A	plus	adjustment	for	family	history	of	diabetes	and	body	mass	index.	The	parameters	for	all	covariates	are	reported	
in Table S4.
(THF+5αTHF)/THE,	tetrahydrocortisol+5α‐tetrahydrocortisol/tetrahydrocortisone; 11β‐HSD,	11β‐hydroxysteroid	dehydrogenase.
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renal	 impairment.	We	identified	inflammation	as	a	major	determinant	
of	GC	activation	by	11β‐HSD	and	as	a	confounder	in	the	correlation	of	
GC	activation	with	renal	impairment,	thereby	expanding	on	knowledge	
from	previous	studies.	Higher	GC	activation	by	11β‐HSD was associated 
with	disturbances	in	glucose	homoeostasis,	offering	novel	evidence	for	
its	clinical	significance	in	patients	with	CKD.	Our	data	agree	with	stud‐
ies	from	preclinical	and	non‐renal	settings	that	 inflammation‐induced	
upregulation	of	11β‐HSD1	can	contribute	to	metabolic	pathology.	This	
study	therefore	adds	credibility	to	the	potential	of	11β‐HSD1 inhibitors 
to	reduce	insulin	resistance	in	populations	with	pro‐inflammatory	con‐
ditions	and	improve	their	cardiovascular	risk.
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